Adrienne I Gordon

US Patent:

20060128708, Jun 15, 2006

Filed:

Jun 14, 2005

Appl. No.:

11/153725

Inventors:

Ivan Diamond - Berkeley CA, US
Adrienne Gordon - Kensington CA, US

International Classification:

A61K 31/53
A61K 31/519
A61K 31/522

US Classification:

514243000, 514263340, 514259310, 514263330

Abstract:

This invention provides a method of mitigating/ameliorating one or more components of addictive behavior associated with chronic consumption of a substance of abuse, or withdrawal therefrom. The method typically involves administering to a subject in need thereof an adenosine A2A receptor antagonist in an amount sufficient to ameliorate said one or more components of addictive behavior.

US Patent:

20090137662, May 28, 2009

Filed:

Mar 27, 2003

Appl. No.:

10/550331

Inventors:

Adrienne S. Gordon - Emeryville CA, US
Ivan F. Diamond - Palo Alto CA, US
Lina Yao - Palo Alto CA, US

International Classification:

A61K 31/352
C12Q 1/02
C12Q 1/68

US Classification:

514455, 435 29, 435 6

Abstract:

This invention pertains to the discovery that a dopamine receptor agonist can activate PKA signaling and/or can act synergistically with an adenosine receptor to activate such signaling. In various embodiments, this invention exploits the synergy between the dopamine receptor pathway and an adenosine receptor pathway to provide methods of mitigating one or more symptoms produced by the chronic consumption of a substance of abuse or to mitigate one or more physiological and/or behavioral symptoms associated with cessation of chronic consumption of a substance of abuse. In certain embodiments, the methods involve administering to the mammal an effective amount of an adenosine receptor antagonist; and an effective amount of a dopamine receptor antagonist; where the effective amount of the adenosine receptor antagonist is lower than the effective amount of an adenosine receptor antagonist administered without said dopamine receptor antagonist.

US Patent:

62550578, Jul 3, 2001

Filed:

Jul 26, 1996

Appl. No.:

8/686796

Inventors:

Adrienne Sue Gordon - Kensington CA
Ivan Diamond - Berkeley CA
Doug Paul Dohrman - San Francisco CA

Assignee:

Ernest Gallo Clinic and Research Center - Emeryville CA

International Classification:

G01N 3353
G01N 33535
G01N 33573
G01N 3398

US Classification:

435 721

Abstract:

The present invention relates to determinable effects of ethanol exposure on the cellular localization and abundance of specific proteins, referred to herein as ethanol indicative proteins. More specifically, the present invention is based, in part, on the discovery that the catalytic C. alpha. subunit of cAMP dependent protein kinase (PKA), which is normally localized in the Golgi apparatus area, appears to translocate to the nucleus upon exposure of a cell to ethanol. The present invention is further based on the observation that the. delta. -subunit of PKC translocates from the Golgi area to the perinucleus and the nucleus in response to ethanol exposure, while the. epsilon. -subunit of PKC migrates from the perinucleus into the cytoplasm. The present invention further relates to the discovery that the detectable amount of the regulatory subunit RI of PKA decreases, while the detectable amount of. alpha. PKC,. delta. PKC and. epsilon. PKC increases upon exposure of a cell to ethanol.

US Patent:

50698958, Dec 3, 1991

Filed:

Nov 9, 1989

Appl. No.:

7/434066

Inventors:

Ivan F. Diamond - Berkeley CA
Adrienne S. Gordon - Kensington CA

International Classification:

A61K 4900

US Classification:

424 10

Abstract:

Alcohol-related disorders are treated by the administration of adenosine antagonists and adenosine agonists to a host. Adenosine antagonists are used to inhibit both acute intoxication and chronic dependence by administering prior to alcohol consumption. The symptoms associated with alcohol withdrawal syndrome may be treated by administering adenosine agonists which reduce the physiological dependence on alcohol during the withdrawal period.